305PD - Clinical profile of germ cell tumor of ovary - A single centre experience

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Gynaecological cancers
Topics Ovarian Cancer
Germ Cell Tumours
Presenter Sandip Ganguly
Citation Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585
Authors S. Ganguly1, B. Biswas1, D. Dabkara2, P. E2, J. Ghosh2, J. Bhaumik3, D. Midha4
  • 1Medical Oncology, TMC - Tata Medical Centre, 700156 - Kolkata/IN
  • 2Medical Oncology, TMC - Tata Medical Centre, Kolkata/IN
  • 3Gynaec Oncology, TMC - Tata Medical Centre, Kolkata/IN
  • 4Oncopathology, TMC - Tata Medical Centre, Kolkata/IN



Germ cell tumor of ovary (GCT) constitutes around 3% of all ovarian neoplasms.


Patients with newly diagnosed ovarian GCT who were being treated in our institute from July’ 2012 to June’2016 were included in this study. Mode of presentation, histology, treatment outcomes and toxicity of the treatment were recorded.


Eighteen patients were treated during this time period with median age of 28 years (range 12 -51 years). Most common mode of presentation was pain abdomen (66%), followed by abdominal distension (22%). Yolk sac tumor (YST) was the most common histology in 11 patients (61%) and the stage at presentation was I in 11(61%), II in 1(0.5%), III in 4(22%) and IV in 2(11%). Two patients didn’t undergo surgery. All patients except two (stage IA dysgerminoma) were treated with chemotherapy (BEP in 13 and EP in 4). Four patients with YST had post treatment elevation of serum Alpha fetoprotein (AFP) level. Two of them had slow resolution of AFP over time. Two patients had persistently elevated AFP levels for which salvage chemotherapy was given. One patient developed grade 4 neuropathy with slow resolution of AFP level and one was lost for follow up Most common toxicity was febrile neutropenia in 9 patients (50%). Two patients developed grade 4 neuropathy. After a median follow up of 17.7 months (range 2.9-41.5 months), median progression free survival (PFS) has not been reached and 3 year PFS is 86.7%.


Ovarian GCT is a highly curable malignancy with multimodality treatment including surgery and cytotoxic chemotherapy with acceptable toxicity. The challenges remain in limiting long-term treatment related toxicity.

Clinical trial indentification

Legal entity responsible for the study





All authors have declared no conflicts of interest.